Selected Drugs Clear All
MultiCheck Results
- 49
Interactions
Avoid/Use Alternative |
||
|
Aloxi
(palonosetron) + Prozac
(fluoxetine) |
||
Avoid/Use Alternativepalonosetron + fluoxetine use alternative or monitor ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects) |
||
|
Aloxi
(palonosetron) + solifenacin
(generic) |
||
Avoid/Use Alternativepalonosetron + solifenacin use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects) |
||
|
Gimoti
(metoclopramide nasal) + propofol
(generic) |
||
Avoid/Use Alternativemetoclopramide + propofol use alternative or monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects) |
||
|
Gimoti
(metoclopramide nasal) + Prozac
(fluoxetine) |
||
Avoid/Use Alternativemetoclopramide + fluoxetine NASAL METOCLOPRAMIDE: avoid combo; ALL OTHER FORMULATIONS: use alternative or decr. metoclopramide dose 50% and monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. metoclopramide levels, risk of CNS depression, psychomotor impairment, serotonin syndrome, other adverse effects (hepatic metab. inhibited, additive effects) |
||
|
Gimoti
(metoclopramide nasal) + Ryanodex
(dantrolene) |
||
Avoid/Use Alternativemetoclopramide + dantrolene use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) |
||
|
Gimoti
(metoclopramide nasal) + sodium oxybate
(generic) |
||
Avoid/Use Alternativemetoclopramide + oxybate use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects) |
||
|
Gimoti
(metoclopramide nasal) + solifenacin
(generic) |
||
Avoid/Use Alternativemetoclopramide + solifenacin use alternative: combo may incr. risk of CNS depression, psychomotor impairment; may decr. metoclopramide efficacy (additive effects; antagonistic effects; absorption of oral metoclopramide affected by delayed gastric emptying) |
||
|
Gimoti
(metoclopramide nasal) + Trileptal
(oxcarbazepine) |
||
Avoid/Use Alternativemetoclopramide + oxcarbazepine use alternative: combo may alter seizure control; may incr. risk of CNS depression, psychomotor impairment (antagonistic effects, metoclopramide may decr. seizure threshold; additive effects) |
||
|
Gimoti
(metoclopramide nasal) + Vanacof
(dexchlorpheniramine/ chlophedianol/ pseudoephedrine) |
||
Avoid/Use Alternativemetoclopramide + chlophedianol use alternative: combo may incr. risk of CNS depression, psychomotor impairment; may decr. metoclopramide efficacy (additive effects; antagonistic effects; absorption of oral metoclopramide affected by delayed gastric emptying) metoclopramide + dexchlorpheniramine use alternative: combo may incr. risk of CNS depression, psychomotor impairment; may decr. metoclopramide efficacy (additive effects; antagonistic effects; absorption of oral metoclopramide affected by delayed gastric emptying) Monitor/Modify Txmetoclopramide + pseudoephedrine monitor BP: combo may incr. risk of HTN (additive effects) |
||
|
propofol
(generic) + sodium oxybate
(generic) |
||
Avoid/Use Alternativepropofol + oxybate use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects) |
||
|
Prozac
(fluoxetine) + sodium oxybate
(generic) |
||
Avoid/Use Alternativefluoxetine + oxybate use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects) |
||
|
Ryanodex
(dantrolene) + sodium oxybate
(generic) |
||
Avoid/Use Alternativedantrolene + oxybate use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects) |
||
|
sodium oxybate
(generic) + solifenacin
(generic) |
||
Avoid/Use Alternativeoxybate + solifenacin use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects) |
||
|
sodium oxybate
(generic) + Trileptal
(oxcarbazepine) |
||
Avoid/Use Alternativeoxybate + oxcarbazepine use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects) |
||
|
sodium oxybate
(generic) + Vanacof
(dexchlorpheniramine/ chlophedianol/ pseudoephedrine) |
||
Avoid/Use Alternativeoxybate + chlophedianol use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects) oxybate + dexchlorpheniramine use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects) |
||
Monitor/Modify Tx |
||
|
Aloxi
(palonosetron) + Gimoti
(metoclopramide nasal) |
||
Monitor/Modify Txpalonosetron + metoclopramide monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects) |
||
|
AY-27255
(vinpocetine) + Prozac
(fluoxetine) |
||
Monitor/Modify Txvinpocetine + fluoxetine monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake) |
||
|
Coreg
(carvedilol) + Gimoti
(metoclopramide nasal) |
||
Monitor/Modify Txcarvedilol + metoclopramide monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects) |
||
|
Coreg
(carvedilol) + lakritze
(licorice (Glycyrrhiza glabra)) |
||
Monitor/Modify Txcarvedilol + licorice monitor BP w/ large amounts of licorice: combo may decr. antihypertensive agent efficacy (antagonistic effects) |
||
|
Coreg
(carvedilol) + propofol
(generic) |
||
Monitor/Modify Txcarvedilol + propofol monitor BP, HR: combo may incr. risk of severe hypotension, bradycardia (additive effects) |
||
|
Coreg
(carvedilol) + Prozac
(fluoxetine) |
||
Monitor/Modify Txcarvedilol + fluoxetine monitor BP, HR: combo may incr. carvedilol levels, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metab. inhibited) |
||
|
Coreg
(carvedilol) + Trileptal
(oxcarbazepine) |
||
Monitor/Modify Txcarvedilol + oxcarbazepine monitor BP, HR: combo may decr. carvedilol levels, efficacy (P-gp-mediated transport possibly induced) |
||
|
Coreg
(carvedilol) + Vanacof
(dexchlorpheniramine/ chlophedianol/ pseudoephedrine) |
||
Monitor/Modify Txcarvedilol + pseudoephedrine monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects) |
||
|
Gimoti
(metoclopramide nasal) + lakritze
(licorice (Glycyrrhiza glabra)) |
||
Monitor/Modify Txmetoclopramide + licorice monitor BP w/ large amounts of licorice: combo may incr. risk of HTN (additive effects) |
||
|
lakritze
(licorice (Glycyrrhiza glabra)) + Vanacof
(dexchlorpheniramine/ chlophedianol/ pseudoephedrine) |
||
Monitor/Modify Txlicorice + pseudoephedrine monitor BP w/ large amounts of licorice: combo may incr. risk of HTN (additive effects) |
||
|
propofol
(generic) + Prozac
(fluoxetine) |
||
Monitor/Modify Txpropofol + fluoxetine monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects) |
||
|
propofol
(generic) + Ryanodex
(dantrolene) |
||
Monitor/Modify Txpropofol + dantrolene monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects) |
||
|
propofol
(generic) + solifenacin
(generic) |
||
Monitor/Modify Txpropofol + solifenacin monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects) |
||
|
propofol
(generic) + Trileptal
(oxcarbazepine) |
||
Monitor/Modify Txpropofol + oxcarbazepine monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, propofol may decr. seizure threshold) |
||
|
propofol
(generic) + Vanacof
(dexchlorpheniramine/ chlophedianol/ pseudoephedrine) |
||
Monitor/Modify Txpropofol + chlophedianol monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects) propofol + dexchlorpheniramine monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects) |
||
|
Prozac
(fluoxetine) + Trileptal
(oxcarbazepine) |
||
Monitor/Modify Txfluoxetine + oxcarbazepine monitor sodium: combo may incr. risk of hyponatremia, seizures, CNS depression, psychomotor impairment (additive effects; antagonistic effects, fluoxetine may decr. seizure threshold) |
||
Caution Advised |
||
|
Augmentin ES-600
(amoxicillin/ clavulanate) + Trileptal
(oxcarbazepine) |
||
Caution Advisedamoxicillin + oxcarbazepine caution advised if seizure disorder use, especially w/ high amoxicillin doses or concomitant renal impairment: combo may alter seizure control (antagonistic effects, amoxicillin may decr. seizure threshold) |
||
|
Prozac
(fluoxetine) + Ryanodex
(dantrolene) |
||
Caution Advisedfluoxetine + dantrolene caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) |
||
|
Prozac
(fluoxetine) + solifenacin
(generic) |
||
Caution Advisedfluoxetine + solifenacin caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) |
||
|
Prozac
(fluoxetine) + Vanacof
(dexchlorpheniramine/ chlophedianol/ pseudoephedrine) |
||
Caution Advisedfluoxetine + chlophedianol caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) fluoxetine + dexchlorpheniramine caution advised: combo may incr. dexchlorpheniramine levels, risk of CNS depression, psychomotor impairment, anticholinergic and other adverse effects (hepatic metab. inhibited, additive effects) |
||
|
Ryanodex
(dantrolene) + solifenacin
(generic) |
||
Caution Adviseddantrolene + solifenacin caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) |
||
|
Ryanodex
(dantrolene) + Trileptal
(oxcarbazepine) |
||
Caution Adviseddantrolene + oxcarbazepine caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) |
||
|
Ryanodex
(dantrolene) + Vanacof
(dexchlorpheniramine/ chlophedianol/ pseudoephedrine) |
||
Caution Adviseddantrolene + chlophedianol caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) dantrolene + dexchlorpheniramine caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) |
||
|
solifenacin
(generic) + Trileptal
(oxcarbazepine) |
||
Caution Advisedsolifenacin + oxcarbazepine caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) |
||
|
solifenacin
(generic) + Vanacof
(dexchlorpheniramine/ chlophedianol/ pseudoephedrine) |
||
Caution Advisedsolifenacin + chlophedianol caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects) solifenacin + dexchlorpheniramine caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects) |
||
|
Trileptal
(oxcarbazepine) + Vanacof
(dexchlorpheniramine/ chlophedianol/ pseudoephedrine) |
||
Caution Advisedoxcarbazepine + chlophedianol caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) oxcarbazepine + dexchlorpheniramine caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) |
||
Additional Considerations |
||
|
fluoxetine
in Prozac
|
||
|
add MAO inhibitor to Interaction Check if recent (14 days) use |
||
|
pseudoephedrine
in Vanacof
|
||
|
add MAO inhibitor to Interaction Check if recent (14 days) use |
||
|
lamivudine
|
||
|
avoid combo of lamivudine oral solution w/ oral products containing sorbitol; may give lamivudine tab formulation or monitor virologic response more frequently if combo cannot be avoided; sorbitol may decr. bioavailability of lamivudine, resulting in decr. levels, efficacy |
||